| 刘理.益气解毒方治疗新型冠状病毒肺炎的临床研究[J].实用中西医结合临床,2023,23(1):1-4 |
| 益气解毒方治疗新型冠状病毒肺炎的临床研究 |
| Clinical Study of Yiqijiedu Decoction in the Treatment of COVID-19 |
| |
| DOI： |
| 中文关键词: 新型冠状病毒肺炎 益气解毒方 新型冠状病毒核酸基因CT值 |
| 英文关键词: COVID-19 Yiqijiedu decoction CT value of nucleic acid gene of novel coronavirus |
| 基金项目:江西省中医药管理局科技计划项目（编号：2022A155） |
|
| 摘要点击次数: 94 |
| 全文下载次数: 55 |
| 中文摘要: |
| 目的：探讨益气解毒方治疗新型冠状病毒肺炎的临床疗效。方法：选取医院2022年1~9月收治的60例新冠肺炎患者，按随机数字表法分为治疗组与对照组，各30例。治疗组给予益气解毒方治疗，对照组给予西医对症治疗。观察两组新型冠状病毒核酸QRF1ab基因及N基因Ct值变化情况、平均住院天数、平均住院费用、中医证候积分、治疗总有效率及不良反应发生情况。结果：治疗后，两组新型冠状病毒核酸QRF1ab基因及N基因Ct值均显著提高，且治疗组优于对照组，差异有统计学意义（P＜0.05）；与对照组相比，治疗组平均住院天数明显减少，平均住院费用明显降低，差异有统计学意义（P＜0.05）；治疗后，两组中医证候积分均低于治疗前，且治疗组更低，差异有统计学意义（P＜0.05）；治疗组治疗总有效率高于对照组（P＜0.05）；治疗组不良反应发生率低于对照组（P＜0.05）。结论：益气解毒方治疗新型冠状病毒肺炎疗效显著，可提升新型冠状病毒核酸QRF1ab基因及N基因Ct值，缩短治疗周期，减少住院费用，改善临床症状，不良反应发生率低。 |
| 英文摘要: |
| Objective: To explore the clinical efficacy of COVID-19 treated by Yiqijiedu decoction. Methods: A total of 60 COVID-19 patients admitted to the hospital from January to September 2022 were selected, and divided into the treatment group and control group use the random number table method, with 30 cases each. The treatment group was given Yiqijiedu decoction, and the control group was given western medicine symptomatic treatment. The changes in Ct value of QRF1ab and N genes, averager hospitalization days, averager hospitalization cost TCM syndrome scores, total response rate and adverse effects of treatment reactions of the two groups were observed. Result: After the treatment, the Ct values of the QRF1ab genes and N genes were significantly improved in both groups, and the treatment group was better than the control group, statistical significance was observed between the groups (P＜0.05). Compared to the control group, in the treatment group, the number of hospital days was significantly reduced, the italization costs were significantly reduced, the differences were statistically significant (P＜0.05). After the treatment, the TCM syndrome scores of two groups were lower than before treatment, and lower in the treatment group, statistical difference between groups (P＜0.05). The total effective rate of the treatment group was higher than that in the control group (P＜0.05). The incidence of adverse reactions in the treatment group was lower than that in the control group (P＜0.05). Conclusion: The Yiqijiedu decoction treatment of COVID-19 is obviously effective, which can significantly improve the Ct value of novel coronavirus nucleic acid QRF1ab gene and N gene, shorten the treatment cycle, reduce hospitalization costs, improve clinical symptoms, and have a low incidence of adverse reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
